Platform
ToleroTech has captured a niche in the field of RNA interference through combining this potent strategy with immunology. Although composition of matter claims for RNA interference-inducing technologies are already covered by patents, ToleroTech’s claim on immune modulation using these technologies provides a strong foundation for our growth and success. The Company’s strength lies in its immunological know-how and expertise. Having access to state of the art technologies and animal models ToleroTech will rapidly commercialize its technologies through strategic alliances or independently.
Dr Min is the inventor of 6 siRNA patents. The core technology of Tolerotech is based on the company-owned patents which covers the methods of targeted siRNA delivery systems and the use of siRNA for treatment of immunologically mediated diseases such as autoimmune diseases and allergic diseases.
- Treatment Methods for Autoimmunity
- US60/939052.
- Treatment of Allergic Disease
US60/939045.
- Targeted Induction of RMA Interference
US60/939053